- Home
- BELFA vs APLS Comparison
BELFA vs APLS Comparison
Compare BELFA & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BELFA | APLS |
|---|---|---|
| Founded | 1949 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BELFA | APLS |
|---|---|---|
| Price | $179.60 | $20.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $31.89 |
| AVG Volume (30 Days) | 29.2K | ★ 1.8M |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | $28.52 | N/A |
| Revenue Next Year | $7.85 | $17.97 |
| P/E Ratio | ★ $40.02 | $100.68 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $53.95 | $16.10 |
| 52 Week High | $227.42 | $30.48 |
Technical Indicators
Market Signals| Indicator | BELFA | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 32.77 | 37.70 |
| Support Level | $175.06 | $18.95 |
| Resistance Level | $227.42 | $20.42 |
| Average True Range (ATR) | 9.73 | 0.96 |
| MACD | -5.64 | -0.18 |
| Stochastic Oscillator | 0.00 | 22.21 |
Price Performance
Historical ComparisonAbout BELFA Bel Fuse Inc.
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.